Canaccord lowered the firm’s price target on DocGo to $11 from $13 and keeps a Buy rating on the shares. The firm said they posted a solid 3Q beat with guidance raise, but sequential GPM decline and cash flow may soften any bounce.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on DCGO:
- DocGo raises FY23 revenue view from $540M-$550M to $615M-$625M, consensus $546M
- DocGo reports Q3 EPS 5c, consensus 6c
- DocGo, Inc. (DCGO) Q3 Earnings Cheat Sheet
- 3 Best Stocks to Buy Now, 10/25/2023, According to Top Analysts
- DocGo gets Health Care Staffing Services Certification from Joint Commission
